Estradiol is an estrogen sold in the U.S. under 17 brand and generic names, for breast neoplasms, hypogonadism and premature menopause. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.
From the FDA label for Imvexxy (application NDA208564). Other estradiol products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.
Generally, when estrogen is prescribed for a postmenopausal woman with a uterus, consider addition of a progestogen to reduce the risk of endometrial cancer. Generally, a woman without a uterus does not need to use a progestogen in addition to her estrogen therapy. In some cases, however, hysterectomized women with a history of endometriosis may need a progestogen [see Warnings and Precautions (5.3 , 5.15) ]. Use estrogen-alone, or in combination with a progestogen, at the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Re-evaluate postmenopausal women periodically as clinically appropriate to determine if treatment is still necessary. Administer IMVEXXY intravaginally: 1 vaginal insert daily for 2 weeks, followed by 1 insert twice weekly (for example, Monday and Thursday). ( 2.1 ) 2.1 Treatment of Moderate to Severe Dyspareunia, a Symptom of Vulvar and Vaginal Atrophy, Due to Menopause Generally, start therapy with the IMVEXXY 4 mcg dosage strength administered intravaginally; insert with the smaller end up for a depth of about two inches into the vaginal canal. Administer 1 insert daily at approximately the same time for 2 weeks, followed by 1 insert twice weekly, every three to four days (for example, Monday and Thursday). Make dosage adjustment based on the clinical response.
The following serious adverse reactions are discussed elsewhere in the labeling: Cardiovascular Disorders [see Boxed Warning , Warnings and Precautions (5.2) ]. Malignant Neoplasms [see Boxed Warning , Warnings and Precautions (5.3) ]. The most common adverse reaction with IMVEXXY (incidence ≥ 3% and greater than placebo) is headache. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Mayne Pharma at 1-844-825-8500 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of IMVEXXY 4 mcg and 10 mcg was assessed in a single, double-blind, parallel-group, placebo-controlled trial (N = 382). The duration of treatment in this trial was 12 weeks (dosing occurred every day for 14 days and then twice weekly thereafter for maintenance). Adverse reactions with an incidence of ≥ 3% in any IMVEXXY group and numerically greater than those reported in the placebo group are listed in Table 1. Table 1: Treatment-Emergent Adverse Reactions Reported at a Frequency of ≥ 3% and Numerically More Common in Women Receiving IMVEXXY Preferred Term IMVEXXY 4 mcg (N=191) IMVEXXY 10 mcg (N=191) Placebo…
Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.
| # | Drug | Rating | Type | Form | Generic? | Typical price | |
|---|---|---|---|---|---|---|---|
| 1 | 72/100 | Prescription | Insert | Generic | $7 | View → | |
| 2 |
Imprint codes, colour and shape from the FDA’s labelling data. Match the imprint on your pill — or search any imprint.
| Imprint | Strength | Colour | Shape | Maker |
|---|---|---|---|---|
| Y;12 | 1.5 mg / 0.03 mg | green | round | — |
| G;16 | 1 mg / 0.02 mg | white | round | — |
| 1C1 | 1 mg / 100 mg | pink | capsule | — |
| 5C1 | 0.5 mg / 100 mg | pink | capsule | — |
| 1C1 | 1 mg / 100 mg | pink, pink | oval | — |
| 5C1 | 0.5 mg / 100 mg |
A combination is a different drug — different dosing, different warnings. It is listed here so you can find it, not so you can substitute it.
From the FDA Enforcement database. A recall covers specific lots — not the drug as a whole.
Alyacen 7/7/7
Failed Impurities/Degradation Specifications: This recall is being initiated due to out-of-specification results total impurities.
Glenmark Pharmaceuticals Inc., USA · May 27, 2026
Estradiol Gel
Defective Container; packets were found to be either empty or partially full.
ANI Pharmaceuticals, Inc. · May 12, 2026
ESTRADIOL, 10 mg, 1 Sterile Pellet, Asteria Health 432 Industrial Ln, Birmingham…
Presence of Foreign substance - potential presence of metal particulate matter
F.H. INVESTMENTS, Inc. (dba Asteria Health) · Jan 26, 2026
ESTRADIOL,15 mg, 1 Sterile Pellet, Asteria Health 432 Industrial Ln, Birmingham,…
Presence of Foreign substance - potential presence of metal particulate matter
F.H. INVESTMENTS, Inc. (dba Asteria Health) · Jan 26, 2026
ESTRADIOL, 20 mg, 1 Sterile Pellet, Asteria Health 432 Industrial Ln, Birmingham…
Presence of Foreign substance - potential presence of metal particulate matter
F.H. INVESTMENTS, Inc. (dba Asteria Health) · Jan 26, 2026
Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.
IMVEXXY is contraindicated in women with any of the following conditions: Undiagnosed abnormal genital bleeding [see Warning and Precautions (5.3) ]. Breast cancer or a history of breast cancer [see Warnings and Precautions (5.3) ]. Estrogen-dependent neoplasia [see Warnings and Precautions (5.3) ]. Active DVT, PE, or history of these conditions [see Warnings and Precautions (5.2) ]. Active arterial thromboembolic disease (for example, stroke or MI), or a history of these conditions [see Warnings and Precautions (5.2) ]. Known anaphylactic reaction, angioedema, or hypersensitivity to IMVEXXY. Hepatic impairment or disease. Protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders. Undiagnosed abnormal genital bleeding ( 4 , 5.3 ) Breast cancer or a history of breast cancer ( 4 , 5.3 ) Estrogen-dependent neoplasia ( 4 , 5.3 ) Active DVT, PE, or history of these conditions ( 4 , 5.2 ) Active arterial thromboembolic disease (for example, stroke or MI), or a history of these conditions ( 4 , 5.2 ) Known anaphylactic reaction, angioedema, or hypersensitivity to IMVEXXY ( 4 ) Hepatic impairment or disease ( 4 , 5.11 ) Protein C, protein S, or antithrombin deficiency, or other known thrombophilic disorders ( 4 )
In vitro and in vivo studies have shown that estrogens are metabolized partially by cytochrome P450 3A4 (CYP3A4). Therefore, inducers or inhibitors of CYP3A4 may affect estrogen drug metabolism. Inducers of CYP3A4, such as St. John's wort (Hypericum perforatum) preparations, phenobarbital, carbamazepine, and rifampin, may reduce plasma concentrations of estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the uterine bleeding profile. Inhibitors of CYP3A4 such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice may increase plasma concentrations of estrogens and may result in side effects. Inducers and inhibitors of CYP3A4 may affect estrogen drug metabolism and decrease or increase the estrogen plasma concentration. ( 7 )
| 70/100 |
| Prescription |
| Spray/Inhaler |
| Generic |
| $7 |
| View → |
| 3 | 70/100 | Prescription | Insert | Generic | $7 | View → |
| 4 | 68/100 | Prescription | Topical | Generic | $7 | View → |
| 5 | 68/100 | Prescription | System | Generic | $7 | View → |
| 6 | 64/100 | Prescription | Topical | Generic | $7 | View → |
| 7 | 64/100 | Prescription | System | Generic | $7 | View → |
| 8 | 64/100 | Prescription | Patch | Generic | $7 | View → |
| 9 | 56/100 | Prescription | System | Generic | $7 | View → |
| 10 | 46/100 | Prescription | Film | Generic | $7 | View → |
| pink, pink |
| oval |
| — |
| J1 | 0.5 mg / 0.1 mg | yellow | round | — |
|---|
| J2 | 1 mg / 0.5 mg | yellow | round | — |
|---|
| MVT;415 | 40 mg / 1 mg / 0.5 mg | yellow | round | — |
|---|